CXL Ophthalmics, LLC – Trademark Portfolio

Entity Type: 16

CXL Ophthalmics, LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 7 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include CXLO, EPI-PREP, EPISMART, and RIBOSTAT. The owner is based in Encinitas, CA.

4354 Manchester Avenue

Encinitas, CA 92024

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CXL Ophthalmics, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (7 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does CXL Ophthalmics, LLC have?

CXL Ophthalmics, LLC has 8 U.S. trademarks filed with the USPTO. Of these, 5 registered, 3 abandoned.

What trademark classes does CXL Ophthalmics, LLC file in?

CXL Ophthalmics, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are CXL Ophthalmics, LLC's most well-known trademarks?

CXL Ophthalmics, LLC's registered trademark portfolio includes well-known marks such as CXLO, EPI-PREP, EPISMART, and RIBOSTAT. These are among 5 currently registered trademarks in the portfolio.

What is CXL Ophthalmics, LLC's trademark registration success rate?

CXL Ophthalmics, LLC has a 63% trademark registration rate, with 5 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.